Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Black patients with ES-SCLC get less chemo but have better survival

Publish date:: November 30, 2020

Key clinical point: Real-world data revealed differences in treatment and survival among Black and White patients with extensive-stage small-cell lung cancer.

Major finding: In multivariate analyses, Black patients were less likely to receive chemotherapy (adjusted odds ratio, 0.85; P = .0004) but had better survival (adjusted hazard ratio, 0.92; P < .0001), compared with White patients.

Study details: A retrospective study of 82,592 patients in the National Cancer Data Base with stage IV small cell lung cancer diagnosed during 2004-2016.

Disclosures: The researchers had no relevant disclosures.

Citation:

Tapan U et al. JTO Clin Res Rep. 2020. doi: 10.1016/j.jtocrr.2020.100109.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Diversity in Medicine

Study shows no link between race and mortality in clear cell RCC,

Black patients with ES-SCLC get less chemo but have better survival,

Family planning issues loom large for female radiation oncologists,